Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Respiratory Viruses

Alpana Waghmare, MD and Janet A. Englund, MD

EPIDEMIOLOGY AND RISK FACTORS

The seasonality of respiratory virus infections among immunocompromised children is similar to that in the community (Fig. 21.1). Respiratory syncytial virus (RSV) typically circulates in the community from November through March, with peak detection in January. Human metapneumovirus follows a similar pattern although often somewhat later. Influenza epidemiology can vary somewhat from year to year, with typical seasons lasting from December to March. Influenza A tends to be more predominant early in the season and influenza B is often seen later in the season. Up-to-date influenza surveillance data for the United States are published on the Centers for Disease Control and Prevention website (https://www.cdc.gov/flu/index.htm), and global surveillance data are maintained by the World Health Organization (https://www.who.int/influenza/surveillance_monitoring/updates/en/).

Parainfluenza viruses (PIVs) vary in seasonality by type. PIV-1 causes croup epidemics in the autumn, generally every other year. PIV-2 infections usually follow the same pattern as PIV-1 and PIV-3 outbreaks, usually occurring in the spring. PIV-3 remains the most common PIV subtype detected in both hospitalized and outpatient studies, but newer molecular epidemiology suggests that either PIV-1 or PIV-4 may be the second most common PIV detected in children, depending on the year. PIV-4 may be detected year-round. Human rhinoviruses (HRVs) and human coronaviruses (HCoVs) are present at moderate levels year-round, although there may be peaks of certain strains over the course of the year.

Exposure to sick contacts is the single most well-described risk factor for respiratory viral acquisition in immunocompromised children. Respiratory viruses are typically transmitted by respiratory secretions through direct contact, via fomites, or by large droplet spread. Entry generally occurs through contact with nasal mucosa or eyes, in contrast to the less permissive oral route. Transmission by small-particle aerosols of RSV has not been proven and, if it occurs, it is an infrequent route. Clinical observations suggest PIVs and human metapneumovirus (HMPV) are transmitted similarly to RSV. Although PIV-1 and PIV-3 have been recovered from air samples collected in the vicinity of infected patients, direct contact and transmission via fomites are likely to be more important. The high initial and subsequent infection rates, as well as outbreaks reported in hematopoietic cell transplant (HCT) recipients in both inpatient and outpatient settings, demonstrate that these viruses spread readily and that a relatively small inoculum is likely able to cause infection.

Epidemiologic patterns of respiratory viral detection in children are roughly similar among HCT recipients, solid organ transplant (SOT) recipients, and oncology patients, although risk factors for viral detection are unique.

HCT Recipients. In a surveillance study of pediatric and adult HCT recipients in the first year after transplant, the most common viruses detected were HRV and HCoV, followed by PIV, adenovirus, RSV, influenza, HMPV, and human bocavirus.1 In a separate multicenter retrospective study of pediatric HCT recipients, 16.6% of patient had at least one respiratory virus detected by PCR in the first year after HCT; younger age was associated with viral detection in univariate analysis. Steroid exposure, neutropenia, and lymphopenia were commonly present in the week before respiratory viral onset.

SOT Recipients. In a large multicenter retrospective study of pediatric SOT recipients, the highest rates of inpatient respiratory virus infection occurred in intestine/abdominal multivisceral transplant recipients, followed by thoracic (heart/lung), liver, and kidney transplants.7 HRV was the most common detected virus (45% of respiratory virus events), followed by RSV (22%), PIV (16%), HMPV (11%), and influenza (10%). Lymphopenia was present in 22% of patients with respiratory virus detected, although this was not evaluated as a risk factor for acquisition.

Oncology Patients. In a large cohort of pediatric cancer patients with fever and neutropenia, at least one respiratory virus was detected in 46% of subjects.4 The most common respiratory viruses detected were HRV, RSV, PIV, influenza, adenovirus, and HMPV.

CLINICAL MANIFESTATIONS

In healthy individuals, most respiratory viral infections are associated with self-limited upper respiratory tract symptoms. Notable exceptions include a stronger association between RSV and bronchiolitis in young infants, PIV and laryngotracheobronchitis, and HRVs and reactive airway disease exacerbations. In immunocompromised patients, respiratory viral infections can be associated with prolonged shedding, lower respiratory tract disease, the need for supplemental oxygen, late airflow obstruction, and even death. Prolonged viral shedding can be associated with persistent respiratory symptoms or can be asymptomatic with durations up to 4 weeks (mean).3 Persistent shedding of PIV in asymptomatic immunocompromised patients for many months has been noted using sensitive molecular detection methods,6 and prolonged shedding has been described for HMPV, HCoVs, and HRVs.6,7 Impairment of T-cell function appears to be commonly associated in children with prolonged shedding; additional risk factors in HCT recipients include initial high viral load, use of steroids, and myeloablative conditioning.5

Initial clinical symptoms related to RSV infection in immunocompromised hosts are similar to those in immunocompetent persons.
Upper respiratory tract infection may progress to lower respiratory tract disease, with likelihood of progression probably related to immune status. Over 1 to 2 weeks, lower respiratory tract involvement may become evident by increasing respiratory distress, worsening hypoxia, and potentially, the need for assisted ventilation. Children or adults who acquire RSV or HMPV during or shortly after chemotherapy for malignancy may also have severe, life-threatening disease. Recovery after assisted ventilation for RSV and HMPV pneumonia occurs but remains uncommon for adult patients despite advances in supportive care. The associated respiratory failure in severely immunocompromised patients may result in multigorgan system failure, with high mortality rates in patients requiring mechanical ventilation. Severe and fatal infection attributed to HMPV has been reported in cancer patients, and HMPV is a relatively common cause of acute respiratory infection in children and adults with malignancy, HCT recipients or organ transplant recipients. Risk factors for severe HMPV infection include lymphopenia, quantitative bronchoalveolar lavage (BAL) viral load has not been associated with mechanical ventilation or death for RSV, PIV, or HMPV in adult patients after HCT; however, the detection of respiratory virus RNA in serum has been associated with fatal outcomes.

PIV infection with lower respiratory tract disease in immunosuppressed patients, particularly those in the immediate posttransplantation period, may result in a similar clinical picture, although the overall mortality rate may be less than that associated with RSV. Many immunocompromised adults with PIV infection first present with symptoms of mild upper respiratory tract disease, but in contrast to RSV, influenza, and HMPV, detection of PIV-1 and PIV-3 in asymptomatic HCT recipients is relatively common, reported in 6 of 17 (35%) infections in a prospective study. Fewer than half of PIV-infected patients have a fever. In severely immunocompromised patients, such as allogeneic HCT recipients less than 100 days after transplant, PIV-3 is the most common PIV subtype detected, reported in 80% of 544 HCT recipients with PIV. In all PIV-infected transplant recipients, infection may progress to lower respiratory tract disease with more serious disease linked to supplemental oxygen requirement, low monocyte counts, and high-dose steroid use. The detection of PIV in BAL or other lower respiratory tract specimens is associated with decreased survival overall in HCT recipients. Higher pretransplant PIV-3 antibody levels were not protective against severe sequelae.

Concomitant infections with other viruses, fungi, or severe graft-versus-host disease are relatively common in adult patients with PIV pneumonitis.

Influenza remains a significant cause of morbidity and mortality in immunocompromised children and adults. In a recent multicenter review of immunocompromised children hospitalized with influenza, immunocompromised children were more likely to present with fever and less likely to present with respiratory distress. They were also less likely to require intensive care but were hospitalized longer. In a study of adult and pediatric HCT and SOT recipients, 22.1% of subjects presented with pneumonia and 66.5% were hospitalized. Prior vaccination was associated with decreased disease severity. Mortality after influenza was 2.9% in adults and 0% in pediatric patients in this study, although higher mortality rates have been previously reported.

With the increased use of molecular diagnostic assays, HRVs and HCoVs are now the most common respiratory viruses detected in immunocompromised patients. HRV can be detected in 20% to 30% of HCT recipients, with progression to lower respiratory tract infection occurring in 17% of patients. Once HRV progresses, mortality rates can be similar to other respiratory viruses, including influenza, PIV, and RSV. In addition to HRVs, other members of the Enterovirus genus, including Enterovirus-D68, can be associated with outbreaks and severe disease. Enterovirus D68 was associated with several hundred cases of severe respiratory illnesses in children in the United States in 2014 and 2018; severe disease was also seen in immunocompromised patients. HCoVs can also be associated with severe disease in the lower respiratory tract and can result in death. Specific considerations for HCT, SOT, and oncology patients are outlined in the following text.

**HCT Recipients.** HCT recipients of all ages may have a more fulminant course after respiratory viral infections, particularly if infection occurs around the time of transplantation. Risk factors for disease progression include lack of engraftment, decreased lymphocyte count, and older age. Evidence of pulmonary infiltrates on chest radiographs may be delayed or absent in patients with severe neutropenia but may become apparent after immune reconstitution or on chest computed tomography or magnetic resonance imaging. In a multicenter retrospective review of pediatric HCT recipients, the all-cause and attributable case-fatality rates within 3 months of hospitalized respiratory viral infection onset were 11% and 5.4%, respectively. Lower respiratory tract infection was rare except in HMPV infections; fever was more common for influenza and HMPV. Multivariate models indicated that onset within 60 days of HCT, steroid use in the 7 days before onset, and
the need for respiratory support at onset were associated with subsequent morbidity or death. Several risk scores have been proposed for adult HCT recipients with respiratory virus infections to predict the risk of progression to lower respiratory tract infection and mortality.19

**SOT Recipients.** In a large multicenter retrospective review, fever was the most common clinical sign detected, although a significant proportion had signs of lower respiratory tract infection at onset (35%).3 Detection of any respiratory viral infection in SOT recipients was associated with an all-cause and attributable case-fatality rate of 4% and 0%, respectively. Receipt of an abdominal/intestinal multivisceral transplant was associated with increased risk of all-cause death in multivariable models. Overall, approximately 50% of patients with respiratory viral infections required some form of respiratory support.

**Oncology Patients.** Adults with leukemia and profound chemotherapy-induced myelosuppression are also at risk of fatal outcome from respiratory viruses. In pediatric patients with fever and neutropenia, episodes caused by different types of respiratory viruses had no differences in the clinical outcome (days of hospitalization, days of fever, oxygen requirement, admission to the intensive care unit, and death) and when comparing patients with a single virus versus coinfection.4

### DISEASE PROPHYLAXIS/PREVENTION

**Influenza Vaccination**

The mainstay of influenza prevention in immunocompromised children is vaccination. Inactivated influenza vaccine (IIV) is recommended for all patients 6 months and older with hematologic malignancies by the Infectious Diseases Society of America (IDSA) guidelines. Vaccination is not recommended for in patients receiving intensive chemotherapy, such as induction or consolidation chemotherapy for acute leukemia, or those who have received anti–B-cell antibodies in the past 6 months.23 Live attenuated influenza vaccine (LAIV) should not be used for immunosuppressed patients except in an outbreak setting when LAIV is determined to be a more effective option owing to strain type. Quadrivalent vaccine should be offered when available. Studies are ongoing to assess the immunogenicity and safety of high-dose influenza vaccination in immunocompromised adults and children.

Influenza vaccination is recommended for all family members, close contacts, and health care workers caring for immunocompromised patients. LAIV is not recommended for household contacts of HCT recipients (within 2 months after transplant), or those with severe immunosuppression as the result of graft-versus-host disease or severe combined immune deficiency.23 If LAIV is given to persons caring for severely immunosuppressed patients, the Centers for Disease Control and Prevention guidelines recommend avoidance of contact for 7 days after vaccination.24

**HCT Recipients.** Immune responses to influenza vaccination are likely more effective further out from HCT. HCT recipients 6 months or older should receive IIV annually starting 6 months after transplant or starting 4 months after transplant during a community outbreak of influenza,23 with second doses recommended for children depending on time from transplant. In reduced intensity HCT, pretransplant vaccination may be appropriate as host immunity is expected to extend into the early transplant period. High-dose vaccination is currently under study in pediatric and adult HCT recipients.

**SOT Recipients.** IDSA guidelines recommend against administering influenza vaccine during intensified immunosuppression, including the first 2-month posttransplant period, because of the likelihood of inadequate response. However, during a community outbreak, IIV can be administered 1 month or later after transplant.23 Earlier vaccination has been supported by recent studies, and more data regarding high-dose vaccine and repeat vaccine dosing within a season are also becoming available.25

**Oncology Patients.** IIV is recommended for all patients older than 6 months with hematologic malignancies, although IDSA guidelines do not recommend vaccination in patients receiving intensive chemotherapy, such as induction or consolidation chemotherapy for acute leukemia, or those who have received anti–B-cell antibodies in the past 6 months.23 Although immune responses are generally lower in children with malignancies, a recent Cochrane review demonstrated reductions in respiratory infections and hospitalization; however, the quality of evidence is low.26

**Influenza Chemoprophylaxis**

Postexposure chemoprophylaxis should be considered in immunosuppressed patients who are in close contact with confirmed influenza cases or during influenza outbreaks.27 In outbreak settings, HCT recipients should receive vaccine immediately if they are 4 months or longer posttransplant. Chemoprophylaxis with oseltamivir or zanamivir should also be initiated for 2 weeks after vaccination while immunity develops.27 Chemoprophylaxis is also recommended for HCT recipients who are less than 24 months posttransplant or those who remain substantially immunocompromised at 24 months or longer after HCT, regardless of vaccination history. For SOT, similar concerns regarding vaccine response in the early posttransplant period exist and chemoprophylaxis should be considered, although recommendations regarding the timing of this strategy are lacking.23 Season-long prophylaxis has been evaluated in a randomized trial of SOT and HCT and showed reduction in culture- or polymerase chain reaction (PCR)-confirmed influenza, although this approach is not universally used and may be targeted to periods of high influenza virus circulation.29 Antiviral resistance may emerge with widespread prophylaxis; drug resistance patterns of circulating strains should be considered when initiating prophylaxis and/or preemptive therapy.

**Other Vaccines in Development**

New advances in the understanding of RSV and HMPV, including the characterization of the RSV fusion (F) protein in its prefusion and postfusion states, have contributed to the development of new RSV vaccines and monoclonal antibodies with the potential to be used for prophylaxis against RSV. Vaccines stimulating antibody directed to the F protein, and specifically to the pre-F protein, are now under development. RSV-specific serum-neutralizing antibodies are efficiently transferred from the mother to the newborn, and ongoing clinical trials may offer potential protection against RSV in family members and health care workers surrounding immunocompromised patients, with the potential to protect these patients. Candidate vaccines against PIV and HMPV, as well as chimeric vaccines containing genes from more than one virus, have also been tested in preclinical models.

**Prophylaxis for Other Viruses**

The identification of serum-neutralizing antibody as a correlate of protection against serious RSV lower respiratory tract disease has been an important advance. Although a humanized monoclonal antibody directed against the RSV F protein, palivizumab, has been licensed since 1998 to prevent RSV disease in young children with underlying cardiac or pulmonary disease, it is also currently used in children who are severely immunocompromised, such as infants with
severe combined immune deficiency or congenital leukemia. Children younger than 24 months who are profoundly immunocompromised may be considered for palivizumab prophylaxis. The development of a potent and long-acting RSV monoclonal antibody directed against the pre-F protein of RSV is undergoing clinical trials in young infants. This, or similar products, may be available in the future to prevent RSV infection or disease in transplant candidates. Passive immunoprophylaxis against PIV and HMPV infection has not been studied in children.

**DIAGNOSIS**

**Sample Type and Handling**

The diagnosis of respiratory viral infections is critically dependent on the type and quality of the clinical specimen and proper handling of the specimen. The preferred specimens for the diagnosis of respiratory viruses in immunocompromised hosts are respiratory secretions obtained as a mid-turbinate or nasopharyngeal swab, nasal wash, nasal aspirate, or bronchoalveolar lavage. A nasal wash specimen is the classic sample used for viral diagnosis by culture and for obtaining samples to assess cytokines or antibodies.

Nasopharyngeal swabs and mid-turbinate swabs are not as sensitive as nasal washes for viral diagnosis using culture but have good diagnostic yields with molecular detection methods. In general, molecular methods of detection are preferred over fluorescent antigen-antibody detection or antigen detection tests in immunocompromised patients. Specimens from children are often more readily diagnosed than those from adults owing to higher viral loads. Other clinical specimens useful for the detection of respiratory viruses in patients of all ages include endotracheal aspirates collected from intubated patients, bronchoalveolar lavage, nasal mucosal epithelium collected by scraping, sputum, and lung tissue obtained by biopsy or at autopsy.

**Nucleic Acid Detection**

Molecular diagnostics, such as multiplex real-time PCR, have replaced cell culture, fluorescent antigen-antibody detection, and antigen detection methodologies because they have high sensitivity and specificity, excellent quality control procedures, and detect a large battery of viral and bacterial pathogens rapidly in a single sample. The use of molecular diagnostics has significantly improved the yield of detection. Numerous rapid multiplex PCR assays are now commercially available that can detect up to 18 or more viruses simultaneously. These assays are sensitive and specific and can detect RSV, HMPV, influenza, HRVs, and HCoVs and differentiate all four PIV subtypes.

**TREATMENT**

**Supportive Treatment**

The potential hypoxemia, apnea, and poor oral intake resulting from infection in young infants, both previously healthy as well as moderately or severely immunocompromised, requires close medical management. Hospitalization may be required for immunocompromised children younger than 1 year, particularly if intravenous (IV) fluid replacement and oxygen therapy are necessary. Systemic or inhaled steroids and bronchodilator therapies are not recommended for treatment of RSV, based on studies that failed to show decreased time in the hospital or improved outcomes. Children with airway obstruction or signs of hypoxia require admission to an intensive care setting for close monitoring, and children with severe disease may require intubation. Supportive care for lower respiratory tract infections caused by PIV and HMPV in immunocompromised hosts similarly may require hospitalization and adjunct therapy, including IV fluids and oxygen support, as well as aggressive therapy of secondary fungal, bacterial, or viral infections.

**Antiviral Treatment**

**Respiratory Syncytial Virus.** Ribavirin, a synthetic guanosine nucleoside, has been licensed for the treatment of RSV respiratory disease in children since 1986 and for the treatment of RSV disease in patients undergoing mechanical ventilation since 1993. Ribavirin is the only approved drug for lower respiratory tract disease caused by RSV, but concerns regarding efficacy, difficulties in administration, and the extremely high cost of the drug have resulted in minimal current use of the drug. Ribavirin is available in aerosolized, oral, and IV forms. Several retrospective studies, including a pooled analysis, have shown aerosolized or oral ribavirin is protective against disease progression to lower respiratory tract infection and mortality in HCT recipients; however, conclusive evidence of efficacy from randomized trials is not available. In patients with leukemia, multivariate models demonstrated similar effects. Oral ribavirin has been retrospectively evaluated in patients receiving chemotherapy or in HCT recipients, suggesting a possible effect of oral ribavirin; however, lack of randomized controls has been a limitation in all studies.

In adult HCT and hematologic malignancy patients with RSV lower respiratory tract infection, use of aerosolized ribavirin was associated with decreased mortality. Oral or IV ribavirin although not statistically significant as the effect was smaller. Of note, some data suggest pediatric HCT recipients with RSV have little morbidity and mortality even without ribavirin therapy. Current international guidelines recommend aerosolized or systemic (oral or IV) ribavirin for intravenous immunoglobulin (IVIG) in patients with RSV upper respiratory tract infection undergoing allogeneic HCT, allogeneic HCT recipients with risk factors for progression to lower respiratory tract infection, and allogeneic HCT patients with lower respiratory tract infection. Recommendations for ribavirin administration for HCT and SOT recipients, and oncology patients are outlined in Table 21.1. Most data and guidance for use of ribavirin are in HCT and oncology; few studies have clearly demonstrated efficacy in SOT recipients, and most data are in lung transplant when both oral and IV ribavirin have been used. For HCT and oncology patients, high-risk situations include patients with lymphopenia; additional risk factors, such as smoking history and use of high-dose total body irradiation, could be used to further risk-stratify patients. In general, aerosolized ribavirin is reserved for subjects with virologically confirmed (BAL positive for RSV) lower respiratory tract infection. It is administered by small-particle aerosol from a solution containing the drug at a concentration of 20 mg/mL sterile water via aerosol for 2 to 20 hours/day, or at a concentration of 60 mg/mL water over 2 hours 3 times daily. Aerosol administration results in high levels of ribavirin in the secretions, with levels exceeding 1000 μM and little systemic absorption. The potential environmental release of ribavirin has caused concern in hospital personnel because of the potential teratogenicity of ribavirin and thus exposure is contraindicated in pregnant women because of its teratogenic potential. Administration of ribavirin via a ventilator, using a high-dose, short-duration method of drug delivery or with a vacuum-exhausted treatment hood, results in minimal or no detectable ribavirin in the rooms of treated children.

Oral ribavirin can be considered in patients weighing more than 15kg; hemolytic anemia is the most important side effect to consider, and patients should be monitored carefully.

Systemic antibody therapy, combined antibody therapy with ribavirin, and aerosolized antibodies have been used to treat RSV disease. The combination of high-titer RSV immunoglobulin and ribavirin has been associated with therapeutic success in uncontrolled studies in...
TABLE 21.1  Prevention and Treatment of Respiratory Viral Infections for Pediatric Hematopoietic Cell Transplant Recipients, Solid Organ Transplant Recipients, and Oncology Patients

| Virus     | Prophylaxis                                                                 | Asymptomatic Shedding | Upper Respiratory Tract Infection | Lower Respiratory Tract Infection |
|-----------|-----------------------------------------------------------------------------|-----------------------|-----------------------------------|----------------------------------|
| RSV       | • Infection control procedures                                               | • Isolation           | • Isolation                       | • Isolation                      |
|           | • Palivizumab for children ≤2 years (during season) undergoing HCT           |                       | • HCT and Oncology; Ribavirin for high-risk situations<sup>a,b,c</sup> | • Low-risk situations in HCT and oncology; consider oral ribavirin<sup>b</sup> |
|           |                                                                       |                       | • SOT: limited data; consider oral ribavirin in lung transplant | • High-risk situations in HCT and oncology; consider aerosolized ribavirin initially followed by oral<sup>b,c</sup> |
|           |                                                                       |                       | • Supportive care                 | • SOT: consider oral or aerosolized ribavirin in lung transplant |
| Influenza A/B | • Infection control procedures                                               | • Isolation           | • Isolation                       | • Supportive care                 |
|           | • Vaccination of contacts                                                   |                       | • Oseltamivir or zanamivir        | • Isofamivir or zanamivir         |
|           | • Vaccination 2-3 weeks before HCT in non-immunodeficient recipients of nonmyeloablative conditioning |                       |                                   | • Consider combination therapy with baloxavir if ≥12 years, or rimantadine (only influenza A) and/or ribavirin |
|           | • Vaccination of post-HCT recipients: starting 6 months after transplant or starting 4 months after transplant during a community outbreak |                       |                                   | • Consider IV peramivir if mechanically ventilated |
|           | • Vaccination of SOT recipients: 2 months after transplant, earlier if outbreak, guidelines may change |                       |                                   | • Supportive care                 |
|           | • Vaccination of oncology patients: no vaccination in patients receiving intensive chemotherapy or those who have received anti-B-cell antibodies in the past 6 months |                       |                                   |                                  |
| PIV       | • Infection control procedures                                               | • Isolation           | • Isolation                       | • Isolation                      |
| HMPV      | • Infection control procedures                                               | • Isolation           | • Consider reduction of steroid dose | • Supportive care                 |
| HRV       | • Infection control procedures                                               | • Isolation           | • Isolation                       | • Consider ribavirin if mechanically ventilated<sup>b</sup> |
| HCoV      | • Infection control procedures                                               | • Isolation           | • Isolation                       | • Isolation                      |
|           |                                                                       |                       | • Supportive care                 | • Supportive care                 |
|           |                                                                       |                       | • Isofamivir or zanamivir         | • Isofamivir or zanamivir         |
|           |                                                                       |                       | • Consider ribavirin if mechanically ventilated<sup>b</sup> | • Supportive care                 |
|           |                                                                       |                       | • Supportive care                 | • Isofamivir or zanamivir         |
|           |                                                                       |                       | • Supportive care                 | • Isofamivir or zanamivir         |

<sup>a</sup>Because of recent price increases, most centers have restrictions on the use of aerosolized ribavirin.
<sup>b</sup>Benefit and dosing of oral ribavirin not clearly understood.
<sup>c</sup>High risk: lymphopenia, smoking history, and use of high-dose total-body irradiation.

HRV, human rhinovirus; HCT, hematopoietic cell transplant; HMPV, human metapneumovirus; HRV, human rhinovirus; IV, intravenous; PIV, parainfluenza virus; RSV, respiratory syncytial virus; SOT, solid organ transplant.

severely immunocompromised adults with RSV disease but has not been confirmed in others. A small, nonrandomized unadjusted analysis in pediatric cancer patients with RSV lower respiratory tract infection suggested a beneficial effect of adjunctive palivizumab or IVIG. Larger studies of HCT recipients with RSV lower respiratory tract infection were unable to demonstrate improved outcomes with adjunctive palivizumab<sup>1,12</sup>; palivizumab is not currently recommended for treatment of RSV infection in any immunocompromised patients.

The duration of ribavirin therapy in immunocompromised hosts is generally at least 3 days. Initiation of antiviral therapy at the stage of upper respiratory tract disease may decrease viral load and possibly reduce the risk of respiratory failure, although most data are based on retrospective uncontrolled data.

Influenza. Early influenza treatment is recommended for all immunocompromised individuals, although there may be benefit even with delayed treatment.<sup>19</sup> M2 inhibitors (amantadine and rimantadine) are currently ineffective, and neuraminidase inhibitors (NAIs) are now first-line therapy for prophylaxis and treatment of influenza. NAIs available in the United States include oral oseltamivir, inhaled zanamivir, IV peramivir, and baloxavir. Clinical efficacy with oseltamivir and inhaled zanamivir has been demonstrated in patients with leukemia or HCT recipients.<sup>19</sup> Many mutations causing oseltamivir and peramivir resistance, including the common H275Y mutation in A(H1N1)pdm09 influenza, do not confer resistance to zanamivir<sup>10</sup> and inhaled zanamivir may be used to treat these strains. IV peramivir used during the 2009 pandemic in severely ill patients was well
tolerated, with evidence of recovery in most patients.\textsuperscript{4} In a randomized trial comparing IV peramivir to oral oseltamivir in hospitalized adults, clinical outcomes were similar.\textsuperscript{42} The optimal duration of peramivir therapy has not been determined for immunocompromised hosts. Longer treatment courses (10 days), although not higher doses, with oseltamivir or zanamivir have been suggested, given the potential for recurrence and the median time for progression to lower respiratory tract infection. Baloxavir was recently approved for treatment of uncomplicated influenza in adults and adolescents\textsuperscript{43}; studies in younger children and immunocompromised hosts are underway.

Multidrug-resistant influenza strains have been identified in immunocompromised patients. Triple-combination antiviral therapy with amantadine, ribavirin, and oseltamivir has been proposed to treat immunocompromised patients with severe influenza A with resistance to oseltamivir. A randomized trial comparing triple-combination antiviral therapy with oseltamivir alone in high-risk adults demonstrated an effect on viral outcomes but no clinical benefit.\textsuperscript{44}

**Parainfluenza.** In a retrospective study of patients with leukemia or HCT recipients with PIV infection, ribavirin had no impact on viral shedding, symptom and hospitalization length, progression to lower respiratory tract infection, or mortality.\textsuperscript{45} A systematic review evaluated aerosolized or systemic ribavirin in 10 retrospective studies in this same population and found no difference in PIV-associated mortality or in progression to lower respiratory tract infection.\textsuperscript{46} Given lack of evidence of clinical efficacy, ribavirin is not recommended for PIV infections. The impact of IVIG alone remains to be determined, although IVIG administration for PIV lower respiratory tract infection did not reduce mortality.\textsuperscript{46}

**Other Respiratory Viruses.** The management of other respiratory viral infections in immunosuppressed patients is generally supportive (Table 21.2). Ribavirin has shown efficacy against HMPV in vitro and in mouse models, with anecdotal reports describing its use in severe infection in immunocompromised hosts (with and without IVIG). Lack of controlled studies of ribavirin and the known toxicities of therapy, including hemolytic anemia, limit its recommendation for HMPV. Currently, no approved antiviral agents exist for treatment of HCoV, HRV, HBoV, or enteroviruses, although some investigational agents are upcoming. The use of IVIG has not been evaluated prospectively and is not routinely recommended for treatment of respiratory viral infections. Some centers routinely check and replete immunoglobulins, but the impact on respiratory virus acquisition and severity is not known.

**New Therapeutics Under Investigation**

New RSV antiviral candidates have been investigated, including presatovir (Gilead Sciences, Foster City, CA), an oral RSV fusion inhibitor, and lumicitabine (Alios/Janssen, Titusville, NJ), an RSV nucleoside analog acting on the RSV virion polymerase. Both antivirals have been tested in human challenge models and have successfully demonstrated antiviral efficacy. Presatovir subsequently underwent two large placebo-controlled clinical efficacy trials for the treatment of RSV in placebo-controlled studies conducted in 185 and 60 adult HSCT patients with upper and lower respiratory tract infections, respectively. Clinical trial endpoints of efficacy were not met for presatovir; studies with lumicitabine have also been suspended. New studies of another nucleoside analog, JNJ-53718678 (Janssen), are underway in young children. Nanobodies, small antibody-like molecules derived from the heavy-chain variable Ig domains that occur naturally in camels, are being developed to be administered by inhalation for the treatment of RSV infection (Ablynx NV, Ghent, Belgium). Vaccines for RSV and PIV are under development, as discussed earlier.

A new potential antiviral therapy for PIV and other sialic acid–binding viruses targets the lung epithelial sialic acid receptor for PIV, thereby preventing viral entry. A novel recombinant sialidase fusion protein, DAS181 (Ansun Biopharma, San Diego, CA), first developed as an antiviral agent for influenza, functions by cleaving sialic acid from the host cell surface, thereby inactivating the host cell receptor recognized by PIV. Successful use of this agent in pediatric and adult transplant recipients under compassionate use has been reported, and clinical trials in immunocompromised subjects are ongoing.

Several studies of novel influenza therapeutics are under investigation, including the NAIs IV zanamivir and laninamivir, monoclonal antibodies, viral polymerase inhibitors, and nitazoxanide. The performance and safety of these newer agents remain to be seen in immunocompromised children.

### Table 21.2 Diagnosis of Respiratory Viral Infections in Pediatric Immunocompromised Patients

| Virus            | Specimen Type  | Real Time RT-PCR Assays | Enzyme-Based Immunoassay | Fluorescent Antigen Detection | Culture       |
|------------------|----------------|------------------------|--------------------------|-------------------------------|---------------|
| Influenza A/B    | Nasopharyngeal aspirate, nasal wash, nasal swab, bronchoalveolar lavage | Widely available | Widely available | Available | Limited availability |
| RSV              | Nasopharyngeal aspirate, nasal wash, nasal swab, bronchoalveolar lavage | Widely available | Widely available | Available | Limited availability |
| HMPV             | Nasopharyngeal aspirate, nasal wash, nasal swab, bronchoalveolar lavage | Not available | Not available | Not available | Limited availability |
| PIVs             | Nasopharyngeal aspirate, nasal wash, nasal swab, bronchoalveolar lavage | Not available | Not available | Not available | Limited availability |
| HRV              | Nasopharyngeal aspirate, nasal wash, nasal swab, bronchoalveolar lavage | Not available | Not available | Not available | Limited availability |
| HCoVs            | Nasopharyngeal aspirate, nasal wash, nasal swab, bronchoalveolar lavage | Not available | Not available | Not available | Limited availability |
| Test advantages  | Sensitive, specific, and ability to be rapid (within 1 hour); typing, determination of viral load, and sequencing possible | Rapid but less sensitive (particularly for low viral loads); relatively inexpensive | Less expensive, rapid; assess quality of specimen; not as sensitive as RT-PCR | Becoming less available and increasingly expensive; not all viruses readily identified in culture (HRV, HCoV, PIV). Results take time but enable typing and analysis of viral strains |

HCoV, human coronavirus; HMPV, human metapneumovirus; HRV, human rhinovirus; PIV, parainfluenza virus; RSV, respiratory syncytial virus; RT-PCR, reverse transcriptase polymerase chain reaction.
INFECTION PREVENTION AND ANTICIPATORY GUIDANCE

Nosocomial Outbreaks

RSV, PIVs, and HMPVs are common causes of nosocomial infections contributing to significant morbidity and mortality in pediatric wards. Nosocomial RSV and PIV infections in adults with leukemia and bone marrow transplants are associated with a high mortality rate. The transmission of identical strains of RSV from the outpatient setting into the hospital has been documented, demonstrating the importance of infection control measures. Nosocomial transmission of HMPV also occurs, with outbreaks in both inpatient and outpatient units. In one study, 15 patients were diagnosed with HMPV within 7 weeks in a tertiary care cancer unit. Molecular subtyping revealed infection with genotype A2a virus, implicating nosocomial transmission. Four patients (26.6%) died of HMPV-associated pneumonia and consequent multiorgan failure.

Nosocomial outbreaks characteristically occur from multiple introductions of community respiratory viral strains as well as patient-to-patient spread (perhaps with health care providers as intermediaries). For prevention of nosocomial transmission, contact isolation precautions are effective, provided that compliance with the policy is maintained among personnel. Hospital personnel may play a role in the transmission of RSV and other respiratory viruses to susceptible patients. Viral spreading can be limited by adherence to strict handwashing procedures and cohorting of infected and exposed individuals. Use of gloves, masks, and goggles in the hospital setting also limits spread. Such strict measures are appropriate in high-risk settings such as pediatric intensive care units or bone marrow transplant wards. Restriction of visitors, including young children, in hospital wards with patients at high risk for RSV infection may be necessary during epidemic periods in the community. Continued compliance through the respiratory virus season by all members of the health care team is critical.

The importance of isolation based on symptoms as opposed to positive viral test results has been shown, but prolonged shedding of respiratory viruses with even minimal symptoms may complicate efforts of infection control. Patients known or suspected to be infected with influenza, RSV, PIV, or HMPV should be kept in contact isolation or cohorted until symptoms have resolved and repeated sensitive diagnostic test results are negative. PIV outbreaks may be difficult to bring under control owing to prolonged asymptomatic shedding, particularly in young children and immunocompromised hosts.

Infections in HCT candidates

Internal guidelines recommend deferral of conditioning therapy in patients with respiratory infections prior to allogeneic HCT, with low strength of evidence. The concern for progressive illness from respiratory viral infection needs to be balanced against concern for underlying disease progression and donor availability. In a large prospective study, respiratory viruses were detected in 116 of 458 HCT patients before transplantation, and viral detection was associated with prolonged hospitalization and lower survival at day 100. This risk was also present in patients with HRV alone. A recent retrospective review of HRV detected in pediatric HCT recipients demonstrated that HRV detection without the presence of lower respiratory tract infection was not associated with decreased days alive and out of the hospital, suggesting the HCT delay is not always warranted. These data should ideally be validated in larger, multicenter studies. The impact of other factors such as viral-specific risk scores, location of infection and viral load, need to be evaluated. In pediatric patients, diagnostic PCR should be considered on all transplant candidates, regardless of symptoms, and transplant delay should be considered, if feasible, with ongoing symptoms or evidence of lower respiratory tract infection.

Infections in SOT candidates

For SOT candidates, there are limited data examining clinical outcomes for pretransplant respiratory viral infections and often organ availability is a significant consideration on proceeding with transplantation. Specific clinical circumstances, such as duration of infection and severity of symptoms, should be considered. Donor transmission of influenza is of particular concern in lung or small bowel transplantation; however, non-lung and non–small bowel organs can be considered after donor antiviral treatment for 48 hours coupled with treatment of the recipient. No clear guidance exists for other respiratory viruses, and decisions regarding organ use from infected donors should be evaluated on a case-by-case basis.
ABSTRACT: Respiratory viruses are commonly detected in both healthy and immunocompromised children. In most healthy children, respiratory viruses are associated with self-limited upper respiratory tract infections and are not accompanied by significant morbidity. In immunocompromised hosts, including hematopoietic cell transplant recipients, solid organ transplant recipients, and oncology patients, respiratory viruses can be associated with significant clinical manifestations, including prolonged viral shedding, lower respiratory tract disease, the need for supplemental oxygen, late airflow obstruction, and even death. This chapter reviews the major respiratory viruses, including respiratory syncytial virus, human metapneumovirus, influenza, parainfluenza viruses, human rhinoviruses, and human coronavirus. Other viruses can manifest as pulmonary infection; however, these viruses are discussed elsewhere (see Chapter 17 for discussion of cytomegalovirus and Chapter 22 for discussion of adenoviruses).

Keywords: hematopoietic cell transplant, immunocompromised, oncology, respiratory virus, solid organ transplant, viral pneumonia
REFERENCES

1. Boeckh M, Campbell A, Xie H, et al. Progression, shedding patterns, and clinical disease associated with respiratory virus infections after allogeneic hematopoietic cell transplantation. *Blood*. 2013;122:3278.

2. Fisher BT, Danziger-Isakov L, Sweet LR, et al. A multicenter consortium to define the epidemiology and outcomes of inpatient respiratory viral infections in pediatric hematopoietic stem cell transplant recipients. *J Pediatric Infect Dis Soc*. 2018;7(4):275-282.

3. Danziger-Isakov L, Steinbach WJ, Paulsen G, et al. A multicenter consortium to define the epidemiology and outcomes of pediatric solid organ transplant recipients with inpatient respiratory virus infection. *J Pediatric Infect Dis Soc*. 2019;8(3):197-204.

4. Torres JP, De la Maza V, Kors L, et al. Respiratory viral infections and coinfections in children with cancer, fever and neutropenia: clinical outcome of infections caused by different respiratory viruses. *Pediatric Infect Dis J*. 2016;35(9):949-954.

5. Nichols WG, Erdman DD, Han A, Zukerman C, Corey L, Boeckh M. Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis. *Biol Blood Marrow Transplant*. 2004;10(1):58-64.

6. Peck AJ, Englund JA, Kuypers J, et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. *Blood*. 2007;110(5):1681-1689.

7. Chu HY, Renaud C, Ficken E, Thomson B, Kuypers J, Englund JA. Respiratory tract infections due to human metapneumovirus in immunocompromised children. *J Pediatric Infect Dis Soc*. 2014;4(4):286-293.

8. Ogimi C, Greninger AL, Waghmare AA, et al. Prolonged shedding of human coronavirus in hematopoietic cell transplant recipients: risk factors and viral genome evolution. *J Infect Dis*. 2017;216(2):203-209.

9. Ogimi C, Xie H, Leisenring WM, et al. Initial high viral load is associated with prolonged shedding of human rhinovirus in allogeneic hematopoietic cell transplant recipients. *Biol Blood Marrow Transplant*. 2018;24(10):2160-2163.

10. Englund JA, Boeckh M, Kuypers J, et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. *Ann Intern Med*. 2006;144(5):344-349.

11. Waghmare A, Campbell AP, Xie H, et al. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. *Clin Infect Dis*. 2013;57(12):1731-1741.

12. Seo S, Campbell AP, Xie H, et al. Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. *Biol Blood Marrow Transplant*. 2013;19(4):589-596.

13. Williams JV, Martino R, Rabella N, et al. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. *J Infect Dis*. 2005;192(6):1061-1065.

14. Whimbey E, Couch RB, Englund JA, et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. *Clin Infect Dis*. 1995;21(2):376-379.

15. Seo S, Xie H, Karron RA, et al. Parainfluenza virus type 3 Ab in allogeneic hematopoietic cell transplant recipients: factors influencing post-transplant Ab titers and associated outcomes. *Bone Marrow Transplant*. 2014;49(9):1205-1211.

16. Seo S, Xie H, Campbell AP, et al. Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplant: viral detection in the lung predicts outcome. *Clin Infect Dis*. 2014;58(10):1357-1368.

17. Collins JP, Campbell AP, Oopeno K, et al. Clinical features and outcomes of immunocompromised children hospitalized with laboratory-confirmed influenza in the United States, 2011-2015. *J Pediatric Infect Dis Soc*. 2018. doi: 10.1093/jpids/piy101.

18. Kumar D, Ferreira VH, Blumberg E, et al. A 5-year prospective multicenter evaluation of influenza infection in transplant recipients. *Clin Infect Dis*. 2018;67(9):1322-1329.

19. Waghmare A, Xie H, Kuypers J, et al. Human rhinovirus infections in hematopoietic cell transplant recipients: risk score for progression to lower respiratory tract infection. *Biol Blood Marrow Transplant*. 2019;25(5):1011-1021.

20. Sse O, Waghmare A, Scott EM, et al. Human rhinovirus detection in the lower respiratory tract of hematopoietic cell transplant recipients: association with mortality. *Haematologica*. 2017;102(6):1120-1130.

21. Waghmare A, Pergam SA, Jerome KR, Englund JA, Boeckh M, Kuypers J. Clinical disease due to enterovirus D68 in adult hematologic malignancy patients and hematopoietic cell transplant recipients. *Blood*. 2015;125(11):1724-1729.

22. Ogimi C, Waghmare AA, Kuypers, et al. Clinical Significance of human coronavirus in bronchoalveolar lavage samples from hematopoietic cell transplant recipients and patients with hematologic malignancies. *Clin Infect Dis*. 2017;64(11):1532-1539.

23. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis*. 2014;58(3):e44-e100.

24. Grohskopf LA, Sojoloz LZ, Olsen SJ, Breeze JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2015-2016 influenza season. *MMWR Morb Mortal Wkly Rep*. 2015;64(30):818-825.

25. Hirzel C, Kumar D. Influenza vaccine strategies for solid organ transplant recipients. *Curr Opin Infect Dis*. 2018;31(4):309-315.

26. Goossen GM, Kremer LC, van de Wetering MD. Influenza vaccination in children being treated with chemotherapy for cancer. *Cochrane Database Syst Rev*. 2013;8:CD006484.

27. Tomblyn M, Chiller T, Eisele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. *Biol Blood Marrow Transplant*. 2009;15(10):1143-1138.

28. Manuel O, Estabrook M, AST Infectious Diseases Community of Practice. RNA respiratory viruses in solid organ transplantation. *Am J Transplant*. 2013;13(suppl 4):212-219.

29. Ison MG, Szakaly P, Shapira MY, Krivan G, Nist A, Dutkowski R. Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients. *Antivir Ther*. 2012;17(6):955-964.

30. Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. *Pediatrics*. 2014;134(3):e1474-502.

31. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases. *Pediatrics*. 1996;97(1):137-140.

32. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. *Blood*. 2011;117(10):2755-2765.

33. Torres HA, Aguiera EA, Mattuzzi GN, et al. Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia. *Haematologica*. 2007;92(9):1216-1263.

34. Foolad F, Aitken SL, Shigle TL, et al. Oral versus aerosolized ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplantation recipients. *Clin Infect Dis*. 2018. doi: 10.1093/cid/ciy760.

35. El-Bietar J, Nelson A, Wallace G, et al. RSV infection without ribavirin treatment in pediatric hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2016;51(10):1382-1384.

36. Hirsch HH, Martino R, Ward KN, Boeckh M, Eisele H, Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. *Clin Infect Dis*. 2013;56(2):258-266.

37. Burrows FS, Carlos LM, Benzimra M, et al. Oral ribavirin for respiratory syncytial virus infection after lung transplantation: efficacy and cost-effectiveness. *J Heart Lung Transplant*. 2015;34(7):9589-62.

38. Chemaly RF, Ghanoto S, Shah DP, et al. Respiratory syncytial virus infections in children with cancer. *J Pediatr Hematol Oncol*. 2014;36(6):e376-e381.

39. Choi SM, Boudreault AA, Xie H, Englund JA, Corey L, Boeckh M. Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. *Blood*. 2011;117(19):5050-5056.

40. Boivin G. Detection and management of antiviral resistance for influenza viruses. *Influenza Other Respir Viruses*. 2013;7(suppl 3):18-23.
41. Hernandez JE, Adiga R, Armstrong R, et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an emergency IND program in the United States. *Clin Infect Dis*. 2011;52(6):695-706.

42. Ison MG, Hui DS, Clezy K, et al. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. *Antivir Ther*. 2013;18(5):651-661.

43. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. *N Engl J Med*. 2018;379(10):913-923.

44. Beigel JH, Bao Y, Beeler J, et al. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. *Lancet Infect Dis*. 2017;17(12):1255-1265.

45. Chemaly RF, Hanmod SS, Rathod DB, et al. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. *Blood*. 2012;119(12):2738-2745; quiz 969.

46. Shah DP, Shah PK, Azzi JM, Chemaly RF. Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: a systematic review. *Cancer Lett*. 2016;370(2):358-364.

47. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. *Bone Marrow Transplant*. 2009;44(8):453-455.

48. Campbell AP, Guthrie KA, Englund JA, et al. Clinical outcomes associated with respiratory virus detection before allogeneic hematopoietic stem cell transplant. *Clin Infect Dis*. 2015;61(2):192-202.

49. Mowerer C, Lee BR, Goyal R, Selvarangan R, Schuster JE. Outcome of children with rhinovirus detection prior to allogeneic hematopoietic cell transplant. *Pediatr Transplant*. 2018;22(8):e13301.

50. Kumar D, Morris MI, Kotton CN, et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. *Am J Transplant*. 2010;10(1):18-25.